CeriBell, Inc. (CBLL) - Stock Analysis
Last updated: Apr 5, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Ceribell is a hot idea fueled by recent FDA 510(k) approvals for neurological devices, strong 31% YoY revenue growth, expanding market penetration, positive technical momentum with a 27% price rise, and favorable healthcare sector dynamics supporting near-term appreciation potential.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠High gross margin ⢠Large liquidity ⢠Negative cash flow CBLL pairs very high gross margins and a strong cash/investment-funded balance sheet with low leverage, but sustained heavy SG&A/R&D, operating losses and negative free cash flow create significant operational and valuation risk.
Price Behavior
Key Price Behavior Insights: ⢠Slightly above SMA ⢠Failed breakout ⢠Moderate volatility Support Level: $17.76 Resistance Level: $19.50 CBLL has traded in a tight range last month, closing just above its last-month SMA (~$18.52) at $18.57, showing modest bullish momentum but stalling below resistance at $19.50 with support near $17.76.
Sentiment & News
Key News Insights: ⢠25â29% guidance ⢠VA and pilot ⢠Pediatric expansion CeriBell guided 2026 revenue growth of 25â29% driven by VA ramp, delirium commercialization pilot, and expanded pointâofâcare EEG adoption (including pediatric/neonatal) after reporting strong 2025 revenue and committed margin focus.
AI Summary
Ceribell now looks less like a pure hardware startup and more like a highâmargin, SaaSâadjacent medâtech whose valuation hinges on materially increasing utilization per installed account and proving early revenue from FedRAMPâenabled virtual assistant/cloud services to convert ~85% gross margins into operating leverage. If utilization lifts and VA monetization accelerate, upside is substantial; conversely, failure to boost revenue per account or continued high SG&A and cash burn would likely force a reârating or dilutive financing.
Description
CeriBell, Inc. develops point-of-care EEG technology that uses AI to support detection and management of neurological conditions in acute care settings. Its Ceribell System pairs a bedside EEG platform with disposable headbands and portable recorders to enable rapid monitoring outside traditional neurodiagnostic labs. The company was incorporated in 2014, changed its name from Brain Stethoscope, Inc. in 2015, and is based in Sunnyvale, California.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Dec 12 | Dec 19 | CBLL | CeriBell, Inc. | Ceribell is a hot idea fueled by recent FDA 510(k) approvals for neurological devices, strong 31% YoY revenue growth, expanding market penetration, positive technical momentum with a 27% price rise, and favorable healthcare sector dynamics supporting near-term appreciation potential. | Closed | +1.2% |